
# Is There a Role for Radiation Therapy and Immunotherapy?

Michael Postow, MD Memorial Sloan Kettering Cancer Center

Presentation Originally Prepared and Presented by Stephen Shiao MD, PhD - Cedars-Sinai Medical Center

## Disclosures

- Consulting Fees:
  - Bristol-Myers Squibb
  - Amgen
- Contracted Research:
  - Bristol-Myers Squibb



Dr. William B. Coley




Dr. William B. Coley

Dr. James Ewing




- Underlying immune mechanisms in radiation
- Effects of ionizing radiation on the immune system
- Radiation and Immunotherapy

## Antitumor Immune Response




Mellman et al. Nature 2011


#### Radiation and Inflammation: Teaching an Old Dog New Tricks



Traditional research in radiation has focused on cell intrinsic mechanisms: DNA damage, ROS production, tumor cell kill/survival

#### T cells are necessary for the full response to RT










- Underlying immune mechanisms in radiation
- Effects of ionizing radiation on the immune system
- Radiation and Immunotherapy

#### Radiation Enhances Multiple Inflammatory Pathways: In Situ Vaccination



#### Radiation can also induce distant effects: "The Abscopal Effect"





...But radiation can also be anti-inflammatory

Like any immune response, and perhaps even more so, the immune system works to control RT-induced inflammation



- Radiation produces a targeted <u>in situ</u> <u>vaccination</u> by triggering immunogenic cell death leading to anti-tumor immune response
- However, tumor mediated suppression and radiation induced suppression act to limit the extent of the RT-induced immune response



# How do we enhance the immune response induced by radiation?

- 1. Augment the anti-tumor immune response induced by RT
- 1. Prevent the innate tumor and radiation-induced suppression of the anti-tumor immune response



- Underlying immune mechanisms in radiation
- Effects of ionizing radiation on the immune system
- Radiation and Immunotherapy

## Augmenting the immune response: Pre-clinical data

- By *increasing* the immune response, multiple groups have shown that immunotherapy can enhance the radiation-induced anti-tumor immune response. Some examples from murine models showing improved efficacy with RT include:
  - <u>Adjuvants</u> CpG (TLR9 agonist), Imiquimod (TLR7 agonist)<sup>1</sup>
  - <u>Cytokines</u> IL-2, IL-12, GM-CSF, Flt-3L<sup>2</sup>
  - <u>T cell Costimulation</u> OX-40L Ab, 4-1BBL Ab, ICOSL Ab<sup>3</sup>
  - <u>Antigen Presentation</u> DC vaccines, Viral vaccines<sup>4</sup>

## Preventing tumor immune suppression: Pre-clinical data

- Preventing inhibition of the immune response has also been shown not only to enhance RT, but also potentiate a systemic response
  - <u>Checkpoint inhibitors</u> Anti-CTLA-4, Anti-PD-1/PD-L1<sup>1</sup>
    - CTLA-4 blockade is synergistic with RT to produce an abscopal response in breast and colon cancer models
    - CTLA-4 blockade + PD-L1 blockade + RT triplet therapy demonstrates increased efficacy to either doublet combination alone.
    - Specific doses are critical: 8 Gy x 3 is more effective than 20 Gy x 1 or 6 Gy x 5 (Dewan MZ, CCR 2009) in mouse models with anti-CTLA-4 therapy
  - <u>TGF-βinhibition<sup>2</sup></u>

## Preventing tumor immune suppression: Pre-clinical data

#### PD-1 blockade + RT


- Sharabi A et al, Cancer Immunol Research 2015 (melanoma)
  - RT and anti–PD-1 immunotherapy altered the ratio of CD4 to CD8 T cells and decreased percentages of CD4 Tregs and absolute increases in CD8 T-cell populations
- Zeng J, *IJROBP* 2013 (glioma): RT+ antiPD-1 tx
  - Increased survival and tumor infiltration by cytotoxic T cells (CD8+/interferon-γ+/tumor necrosis factor-α+) and decreased regulatory T cells (CD4+/FOXP3)

## Preventing tumor immune suppression: Clinical data


<u>Ipilimumab</u> CTLA-4 inhibition allows increased proliferation and function of activated T-cells, including tumor-specific CTLs

• Several retrospective studies showed safety combining ipilimumab and radiotherapy<sup>1,2</sup>

#### RT/Ipi can induce distant immunemediated tumor regression



#### Clinical examples of the abscopal effect



Vitiligo and response after 11 months

Doing well 1.5 years after SRS

Sullivan et al. NEJM 2013

## Augmenting the immune response: Clinical examples

- IL-2 and RT (Sueng SK Sci Transl Med 2012)
  - IL-2 is a cytokine necessary for growth, proliferation and differentiation of T-cells to become antigen-specific CD4+ and CD8+ T cells
  - RT+IL-2 increased inflammatory cytokine production and upregulation of MHC-I and B7.1
  - IL-2 +SBRT in metastatic RCC/melanoma showed a CR in 8/12 pts
  - Higher frequency of proliferating CD4+ T cells with and early activated memory phenotype in responders
- DC Vaccination and RT (Finkelstein Immunotherapy 2012)
  - High risk prostate cancer pts tx with ADT +EBRT 45Gy+ DC injections into prostate
  - Autologous DCs were cultured in vitro and reintroduced directly into the prostate
  - Serial bx show tumor cell apoptosis and increase in tumor- infiltrating CD8+ T-cells and prostate specific CD8+ T cells in the peripheral blood



- Irradiation of a tumor causes response at distant metastatic site
- Probably mediated by the immune system
- Although RT can cause cross-priming of CTLs, the effect of RT elsewhere may be weak
- With the addition of immunotherapies, this rare effect may be more reproducible

## Summary for RT + Immunotherapy

- Given that RT is already immunogenic, combinations of RT and various immunotherapies showed enhanced anti-tumor immunity, but limited data showing clinical efficacy
- RT+ immunotherapy in pre-clinical and clinical studies show:
  - Enhanced cross-priming and stimulation of tumorspecific CTLs
  - Specific fractionation schemes seem to enhance the immunogenicity of RT
  - Neutralizing the immunosuppressive effects of the tumor microenvironment can lead to enhanced responses locally and systemically



- Preclinical data for immunogenicity of RT
- Preclinical data for enhancing efficacy of checkpoint blockade with RT
- Clinical anecdotes
- Whether RT and immunotherapy are synergistic in a clinical context remains unknown and subject to ongoing prospective trials